ATE455853T1 - Antikörper gegen geschädigtes gewebe - Google Patents

Antikörper gegen geschädigtes gewebe

Info

Publication number
ATE455853T1
ATE455853T1 AT03775858T AT03775858T ATE455853T1 AT E455853 T1 ATE455853 T1 AT E455853T1 AT 03775858 T AT03775858 T AT 03775858T AT 03775858 T AT03775858 T AT 03775858T AT E455853 T1 ATE455853 T1 AT E455853T1
Authority
AT
Austria
Prior art keywords
antibodies against
cell
genes
cancer
damaged tissue
Prior art date
Application number
AT03775858T
Other languages
English (en)
Inventor
Masayuki Tsuchiya
Masami Suzuki
Kenji Yoshida
Etsuko Fujii
Kouichi Matsubara
Hiroyuki Tsunoda
Original Assignee
Chugai Pharmaceutical Co Ltd
Pharmalogicals Res Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd, Pharmalogicals Res Pte Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ATE455853T1 publication Critical patent/ATE455853T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT03775858T 2002-11-22 2003-11-21 Antikörper gegen geschädigtes gewebe ATE455853T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002339241 2002-11-22
PCT/JP2003/014919 WO2004048571A1 (ja) 2002-11-22 2003-11-21 病巣組織に対する抗体

Publications (1)

Publication Number Publication Date
ATE455853T1 true ATE455853T1 (de) 2010-02-15

Family

ID=32375769

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03775858T ATE455853T1 (de) 2002-11-22 2003-11-21 Antikörper gegen geschädigtes gewebe

Country Status (7)

Country Link
US (1) US20060235207A1 (de)
EP (1) EP1571211B1 (de)
JP (1) JP4690046B2 (de)
AT (1) ATE455853T1 (de)
AU (1) AU2003284427A1 (de)
DE (1) DE60331101D1 (de)
WO (1) WO2004048571A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
EP1746157A4 (de) 2004-04-27 2009-02-18 Chugai Pharmaceutical Co Ltd Verfahren zur plasmazellproliferation
AU2013204620B2 (en) * 2007-01-05 2015-09-17 University Of Zurich Method of Providing Disease-Specific Binding Molecules and Targets
PT2099826E (pt) * 2007-01-05 2014-01-09 Univ Zuerich Anticorpo anti-beta-amilóide e suas utilizações
HRP20140049T1 (hr) 2007-01-05 2014-02-28 University Of Zürich Anti beta-amiloid antitijela i njihova upotreba
AU2011265453B9 (en) * 2007-01-05 2013-09-12 University Of Zurich Method of providing disease-specific binding molecules and targets
ES2523194T3 (es) * 2007-03-13 2014-11-21 University Of Zurich Anticuerpo monoclonal humano específico para cada tumor
WO2009131605A2 (en) * 2008-01-28 2009-10-29 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
CA2730073A1 (en) * 2008-07-09 2010-01-14 University Of Zurich Method of promoting neurogenesis
WO2010069603A1 (en) 2008-12-19 2010-06-24 Neurimmune Therapeutics Ag Human anti-alpha-synuclein autoantibodies
US20120034626A1 (en) * 2010-03-03 2012-02-09 Morre D James Neoplasia-Specific Autoantibodies and Methods
EA201291065A1 (ru) 2010-04-16 2013-03-29 Байоджен Айдек Ма Инк. Антитела против vla-4
CN103796679B (zh) 2011-06-23 2016-10-19 比奥根国际神经科学公司 抗-α突触核蛋白结合分子
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
AU2018321335B2 (en) 2017-08-22 2025-08-14 Biogen Ma Inc. Pharmaceutical compositions containing anti-beta amyloid antibodies
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体
KR20220102626A (ko) * 2019-11-08 2022-07-20 엑셀라 바이오사이언시스 인코포레이티드 미세모세관 어레이들로부터 레이저-기반 단일 세포 회수를 위한 장치 및 방법
WO2021154530A1 (en) * 2020-01-27 2021-08-05 Vanderbilt University Human anti-dengue antibodies and methods of use therefor
CA3184157A1 (en) * 2020-06-26 2021-12-30 Phaim Pharma Ltd Psoriasis and other autoimmune diseases antigen immune modulator (aim) therapeutic platform
JP2023540339A (ja) * 2020-09-04 2023-09-22 インパクト バイオ ユーエスエー インコーポレイテッド 癌治療に使用するためのバイシストロン性阻害性キメラ抗原受容体（ｉＣＡＲ）／活性化キメラ抗原受容体（ａＣＡＲ）構築物
EP4297786A4 (de) * 2021-02-23 2025-01-22 Pandion Operations, Inc. Pd-1-antikörper, polypeptide und verwendungen davon

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5495002A (en) * 1984-01-31 1996-02-27 Akzo N.V. Tumor associated monoclonal antibody 123AV16
JPH06141884A (ja) * 1992-11-06 1994-05-24 Hagiwara Yoshihide 抗癌ヒトモノクローナル抗体のアミノ酸配列及びそれをコードするｄｎａ塩基配列
US20020193296A1 (en) * 1997-02-25 2002-12-19 Jiangchun Xu Compositions and methods for the therapy and diagnosis of prostate cancer
US6676927B1 (en) * 1999-01-20 2004-01-13 The Rockefeller University Animal model and methods for its use in the selection of cytotoxic antibodies
WO2001068682A1 (en) * 2000-03-10 2001-09-20 Large Scale Biology Corporation Self antigen vaccines for treating b cell lymphomas and other cancers
EP1746157A4 (de) * 2004-04-27 2009-02-18 Chugai Pharmaceutical Co Ltd Verfahren zur plasmazellproliferation

Also Published As

Publication number Publication date
JPWO2004048571A1 (ja) 2006-04-06
DE60331101D1 (de) 2010-03-11
AU2003284427A1 (en) 2004-06-18
EP1571211B1 (de) 2010-01-20
EP1571211A4 (de) 2006-03-22
WO2004048571A1 (ja) 2004-06-10
AU2003284427A8 (en) 2004-06-18
JP4690046B2 (ja) 2011-06-01
EP1571211A1 (de) 2005-09-07
US20060235207A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
DE60331101D1 (de) Antikörper gegen geschädigtes gewebe
WO2005062977A3 (en) Prostate cancer specific internalizing human antibodies
ATE330032T1 (de) Verfahren zur erhaltung der dns-integrität
DK0917571T3 (da) Hidtil ukendt agoutirelateret gen
WO2009073546A3 (en) Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)
WO2004097052A3 (en) Methods for prognosis and treatment of solid tumors
IL160315A0 (en) Externally-applied high intensity focused ultrasound (hifu) for pulmonary vein isolation
DE502004009142D1 (de) Verfahren zur herstellung substituierter 3-aryl-butyl-aminverbindungen
WO2002090539A3 (en) Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases
CL2007003649A1 (es) Un conjugado de molecula asociado a anticuerpo monoclonal humano anti-cd70; composicion que comprende al conjugado de molecula asociado a anticuerpo; metodo de inhibicion del crecimiento de celulas tumorales que expresan cd70.
WO2006036173A3 (en) Frizzled proteins and detection and treatment of cancer
WO2006036175A3 (en) Wnt proteins and detection and treatment of cancer
IL176522A0 (en) Universal amplification of fragmented rna
WO2004043379A3 (en) Chemical compounds
WO2009049966A3 (en) Methods and tools for prognosis of cancer in her2+ patients
WO2006034328A3 (en) Wnt proteins and detection and treatment of cancer
WO2007059190A3 (en) Compositions of and methods of using stabilized psma dimers
WO2005033133A3 (en) Polynucleotides encoding erbb-2 polypeptides and kits and methods using same
AU2003276765A1 (en) Method for amplifying unknown dna sequence adjacent to known sequence
WO2003020019A3 (en) Methods and compositions for pearl oyster cultivation
WO2002047710A3 (en) Use of inhibitors of lyn-associated signal transduction (last) in the treatment of prostate cancer
SE9900615L (sv) Metod och kit för tidig förutsägelse av cancer
AUPS064202A0 (en) Improved method for the analysis of nucleic acid samples
WO2006039638A3 (en) Treating renal cell carcinoma with an anti-tnf human antibody or fragment
DE602004030231D1 (de) Pyrimidinonverbindungen als calcilytica

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties